The FDA has approved ANI Pharmaceuticals’ (NASDAQ:ANIP) marketing application for Potassium Citrate Extended-Release Tablets USP, 10 mEq and 15 mEq for the management of renal tubular acidosis with calcium stones (kidney stones), hypocitraturic calcium oxalate nephrolithiasis of any etiology and uric acid lithiasis with or without calcium stones.
Per IQVIA, the U.S. market is ~$75M.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.